ICON PLC Stock Price, News & Analysis

ICON plc (NASDAQ: ICLR) reported its Q1 2023 financial results with net business wins of $2,415 million and a book-to-bill ratio of 1.22. Revenues reached $1,978.6 million, up 4.0% year-over-year. The adjusted EBITDA stood at $399.1 million, 20.2% of revenue, reflecting a 17.2% increase. GAAP net income was $116.7 million, or $1.41 per share. The company reaffirmed its full-year 2023 revenue guidance in the range of $7,940 - $8,340 million and adjusted EPS guidance of $12.40 - $13.05, indicating a year-on-year growth of 5.5% to 11.1%. Cash flow from operations amounted to $175.5 million, with a net debt of $4.2 billion and a debt-to-adjusted EBITDA ratio of 2.8x.

ICON plc (NASDAQ: ICLR) has announced that it will release its financial results for Q1 2023 after market close on April 26, 2023. A conference call and webcast to discuss these results will occur on April 27, 2023, at 8:00 AM ET. The company, headquartered in Dublin, employs approximately 41,100 people across 111 locations in 53 countries, focused on healthcare intelligence and clinical research.

The press release emphasizes the importance of these financial results and cautions that forward-looking statements are subject to risks and uncertainties, including the impact of COVID-19 and market conditions.

LEO Pharma and ICON plc (NASDAQ: ICLR) have announced a strategic partnership aimed at enhancing patient-centric clinical trial execution. This initiative, dubbed PACE, seeks to address current clinical development challenges by improving access to innovative dermatology treatments. The partnership will utilize a hybrid outsourcing model, allowing for scalable efficiencies in clinical trials, decentralized clinical trials, and leveraging ICON's extensive resources. This collaboration aligns with LEO Pharma's 2030 strategy, focusing on delivering treatments faster and supporting sustainable business practices.